RT @DaveGennert: A whirlwind overview of #myeloma #immunotherapy developments & targets from @ESmithMDPhD at #AACRbcd24. Highlighting work…
RT @DaveGennert: A whirlwind overview of #myeloma #immunotherapy developments & targets from @ESmithMDPhD at #AACRbcd24. Highlighting work…
RT @DaveGennert: A whirlwind overview of #myeloma #immunotherapy developments & targets from @ESmithMDPhD at #AACRbcd24. Highlighting work…
A whirlwind overview of #myeloma #immunotherapy developments & targets from @ESmithMDPhD at #AACRbcd24. Highlighting work with @fdezdelarrea & @BrentjensRenier on BCMA+GPRC5D targeting to avoid antigen escape in MM @BCD_AACR: https://t.co/y7USso3Ko
RT @HansScheurer: Whats next…. Study combining BCMA & GPRC5D target #myeloma @MMTrials @Myeloma_Doc @MyelomaEurope
RT @BCD_AACR: Read BCD’s top five cited articles: Addressing BCMA-escape with dual-targeted #CARTcell therapy, by @fdezdelarrea et al. http…
RT @HansScheurer: Whats next…. Study combining BCMA & GPRC5D target #myeloma @MMTrials @Myeloma_Doc @MyelomaEurope
RT @ESmithMDPhD: Next Steps: A multicenter trial of a similar GPRC5D product (NCT04674813). BCMA/GPRC5D dual-targeting (https://t.co/jOoJ…
RT @HansScheurer: Whats next…. Study combining BCMA & GPRC5D target #myeloma @MMTrials @Myeloma_Doc @MyelomaEurope
Whats next…. Study combining BCMA & GPRC5D target #myeloma @MMTrials @Myeloma_Doc @MyelomaEurope
Dual-targeting
Next Steps: A multicenter trial of a similar GPRC5D product (NCT04674813). BCMA/GPRC5D dual-targeting (https://t.co/jOoJKemdR4; NCT05431608) trial. In the lab @DanaFarber we are working on novel approaches for gene/cell/mRNA immunotx of MM & solid t
RT @fdezdelarrea: Top five cited articles at @BCD_AACR @ESmithMDPhD @MSKCancerCenter
RT @DrMiguelPerales: Really cool to see 3 of top 5 @BCD_AACR cited papers from @MSKCancerCenter including studies by @DavidJChungMD @fdezde…
RT @DrMiguelPerales: Really cool to see 3 of top 5 @BCD_AACR cited papers from @MSKCancerCenter including studies by @DavidJChungMD @fdezde…
RT @DrMiguelPerales: Really cool to see 3 of top 5 @BCD_AACR cited papers from @MSKCancerCenter including studies by @DavidJChungMD @fdezde…
Interesante approach en #MielomaMultiple, #CART dirigido a la vez a BCMA y GPRC5D. La investigación es VIDA 💕 .!! Defining an Optimal Dual-Targeted CAR T Therapy Approach Simultaneously Targeting BCMA + GPRC5D to Prevent BCMA Escape–Driven Relapse in MM.
RT @fdezdelarrea: Top five cited articles at @BCD_AACR @ESmithMDPhD @MSKCancerCenter
RT @DrMiguelPerales: Really cool to see 3 of top 5 @BCD_AACR cited papers from @MSKCancerCenter including studies by @DavidJChungMD @fdezde…
RT @DrMiguelPerales: Really cool to see 3 of top 5 @BCD_AACR cited papers from @MSKCancerCenter including studies by @DavidJChungMD @fdezde…
RT @DrMiguelPerales: Really cool to see 3 of top 5 @BCD_AACR cited papers from @MSKCancerCenter including studies by @DavidJChungMD @fdezde…
RT @DrMiguelPerales: Really cool to see 3 of top 5 @BCD_AACR cited papers from @MSKCancerCenter including studies by @DavidJChungMD @fdezde…
RT @DrMiguelPerales: Really cool to see 3 of top 5 @BCD_AACR cited papers from @MSKCancerCenter including studies by @DavidJChungMD @fdezde…
RT @DrMiguelPerales: Really cool to see 3 of top 5 @BCD_AACR cited papers from @MSKCancerCenter including studies by @DavidJChungMD @fdezde…
RT @DrMiguelPerales: Really cool to see 3 of top 5 @BCD_AACR cited papers from @MSKCancerCenter including studies by @DavidJChungMD @fdezde…
RT @DrMiguelPerales: Really cool to see 3 of top 5 @BCD_AACR cited papers from @MSKCancerCenter including studies by @DavidJChungMD @fdezde…
Really cool to see 3 of top 5 @BCD_AACR cited papers from @MSKCancerCenter including studies by @DavidJChungMD @fdezdelarrea @MalinHultcrantz @MSK_DeptOfMed #mmsm #COVID19 #CARTcells
RT @BCD_AACR: Read BCD’s top five cited articles: Addressing BCMA-escape with dual-targeted #CARTcell therapy, by @fdezdelarrea et al. http…
RT @fdezdelarrea: Top five cited articles at @BCD_AACR @ESmithMDPhD @MSKCancerCenter https://t.co/GpfSo5pDdG
RT @BCD_AACR: Read BCD’s top five cited articles: Addressing BCMA-escape with dual-targeted #CARTcell therapy, by @fdezdelarrea et al. http…
RT @fdezdelarrea: Top five cited articles at @BCD_AACR @ESmithMDPhD @MSKCancerCenter
Top five cited articles at @BCD_AACR @ESmithMDPhD @MSKCancerCenter
Read BCD’s top five cited articles: Addressing BCMA-escape with dual-targeted #CARTcell therapy, by @fdezdelarrea et al. https://t.co/2ZEeRzYWK9 @MSKCancerCenter https://t.co/Haqeqg8MS8
RT @TaliLev123: Very nice presentation by Eric Smith at #TAE_IO22 including the story published in @BCD_AACR @_TanyaBondar_ https://t.co/Mz…
RT @TaliLev123: Very nice presentation by Eric Smith at #TAE_IO22 including the story published in @BCD_AACR @_TanyaBondar_ https://t.co/Mz…
RT @TaliLev123: Very nice presentation by Eric Smith at #TAE_IO22 including the story published in @BCD_AACR @_TanyaBondar_ https://t.co/Mz…
RT @TaliLev123: Very nice presentation by Eric Smith at #TAE_IO22 including the story published in @BCD_AACR @_TanyaBondar_ https://t.co/Mz…
Very nice presentation by Eric Smith at #TAE_IO22 including the story published in @BCD_AACR @_TanyaBondar_ https://t.co/MzHJp1qVYJ
RT @RahulBanerjeeMD: 3/ Study #2: Bicistronic >> tandem for BCMA & GPRC5D https://t.co/qRjypeuMjT CC: @ninashah33 @SandyWong02111 @Noopur…
3/ Study #2: Bicistronic >> tandem for BCMA & GPRC5D https://t.co/qRjypeuMjT CC: @ninashah33 @SandyWong02111 @NoopurRajeMD @szusmani @DrKrinaPatel @SurbhiSidanaMD @rajshekharucms @End_myeloma @ManniMD1 @bdermanmd @YLeyfman @DavidJChungMD @DMadd
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @BCD_AACR: Crystal Mackall @cm35c is hosting #ASH21 workshop on dual targeting #CARTcells. See what @fdezdelarrea can do with dual-CARs…
Crystal Mackall @cm35c is hosting #ASH21 workshop on dual targeting #CARTcells. See what @fdezdelarrea can do with dual-CARs in multiple myeloma: https://t.co/NWpNR2TVfl
RT @_TanyaBondar_: #AACRMDT21 Eric Smith talks about mechanisms of resistance to BCMA-targeted therapies and ways to overcome it, including…
RT @_TanyaBondar_: #AACRMDT21 Eric Smith talks about mechanisms of resistance to BCMA-targeted therapies and ways to overcome it, including…
RT @_TanyaBondar_: #AACRMDT21 Eric Smith talks about mechanisms of resistance to BCMA-targeted therapies and ways to overcome it, including…
RT @_TanyaBondar_: #AACRMDT21 Eric Smith talks about mechanisms of resistance to BCMA-targeted therapies and ways to overcome it, including…
#AACRMDT21 Eric Smith talks about mechanisms of resistance to BCMA-targeted therapies and ways to overcome it, including dual-CART described in this article: https://t.co/bmXF1hUVBA See this @BCD_AACR review on CART response and resistance in myeloma: http
Looking forward to Eric Smith's talk on #celltherapy in #myeloma? Read his article on this topic: https://t.co/ZiyJgEpiuq #mmsm #CARTcell https://t.co/Vtklu9LqMU
RT @fdezdelarrea: Thanks a lot @AACR journals for including our article in this collection. Targeting BCMA and GPRC5D to Prevent BCMA Escap…
RT @fdezdelarrea: Thanks a lot @AACR journals for including our article in this collection. Targeting BCMA and GPRC5D to Prevent BCMA Escap…
RT @fdezdelarrea: Thanks a lot @AACR journals for including our article in this collection. Targeting BCMA and GPRC5D to Prevent BCMA Escap…
RT @fdezdelarrea: Thanks a lot @AACR journals for including our article in this collection. Targeting BCMA and GPRC5D to Prevent BCMA Escap…
RT @fdezdelarrea: Thanks a lot @AACR journals for including our article in this collection. Targeting BCMA and GPRC5D to Prevent BCMA Escap…
Thanks a lot @AACR journals for including our article in this collection. Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma https://t.co/C43d8XhIe6 @sloan_kettering @idibaps @hematoclinicbcn #AACR21 @ESmithMDPhD @BCD_AACR
RT @BrunoPaiva_UNAV: Two papers published the same day in @NatureComms showing selection of CD19 and BCMA negative clones in ALL and MM aft…
RT @BrunoPaiva_UNAV: Two papers published the same day in @NatureComms showing selection of CD19 and BCMA negative clones in ALL and MM aft…
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma | Blood Cancer Discovery https://t.co/HRk8uvsEsC
RT @BrunoPaiva_UNAV: Two papers published the same day in @NatureComms showing selection of CD19 and BCMA negative clones in ALL and MM aft…
RT @BrunoPaiva_UNAV: Two papers published the same day in @NatureComms showing selection of CD19 and BCMA negative clones in ALL and MM aft…
RT @BrunoPaiva_UNAV: Two papers published the same day in @NatureComms showing selection of CD19 and BCMA negative clones in ALL and MM aft…
RT @BrunoPaiva_UNAV: Two papers published the same day in @NatureComms showing selection of CD19 and BCMA negative clones in ALL and MM aft…
RT @BrunoPaiva_UNAV: Two papers published the same day in @NatureComms showing selection of CD19 and BCMA negative clones in ALL and MM aft…
RT @BrunoPaiva_UNAV: Two papers published the same day in @NatureComms showing selection of CD19 and BCMA negative clones in ALL and MM aft…
RT @BrunoPaiva_UNAV: Two papers published the same day in @NatureComms showing selection of CD19 and BCMA negative clones in ALL and MM aft…
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma https://t.co/eMkI8tzEPf @DrGauravNarula @CTCTC_tmc @bagalbp
RT @BrunoPaiva_UNAV: Two papers published the same day in @NatureComms showing selection of CD19 and BCMA negative clones in ALL and MM aft…
RT @BrunoPaiva_UNAV: Two papers published the same day in @NatureComms showing selection of CD19 and BCMA negative clones in ALL and MM aft…
RT @BrunoPaiva_UNAV: Two papers published the same day in @NatureComms showing selection of CD19 and BCMA negative clones in ALL and MM aft…
RT @BrunoPaiva_UNAV: Two papers published the same day in @NatureComms showing selection of CD19 and BCMA negative clones in ALL and MM aft…
Two papers published the same day in @NatureComms showing selection of CD19 and BCMA negative clones in ALL and MM after CAR T cell infusion. Time for dual-targeted CAR T-cell therapy @fdezdelarrea? #mmsm https://t.co/XGWZ6KOdUN https://t.co/6bqTq0LcEy h
RT @_TanyaBondar_: #ASH20: @ESmithMDPhD outlines a bright future for #CAR_T cells in #myeloma. Comparison of different approaches to dual B…
RT @_TanyaBondar_: #ASH20: @ESmithMDPhD outlines a bright future for #CAR_T cells in #myeloma. Comparison of different approaches to dual B…
RT @_TanyaBondar_: #ASH20: @ESmithMDPhD outlines a bright future for #CAR_T cells in #myeloma. Comparison of different approaches to dual B…
#ASH20: @ESmithMDPhD outlines a bright future for #CAR_T cells in #myeloma. Comparison of different approaches to dual BCMA + GPRC5 antigen targeting, featured in his talk, is free to read @BCD_AACR here: https://t.co/zalQAECTX9 @fdezdelarrea @DanaFarber @
RT @BCD_AACR: Now presenting at #ASH20: Read this recent paper in which @ESmithMDPhD, Renier Brentjens, @fdezdelarrea, and colleagues prese…
RT @BCD_AACR: Now presenting at #ASH20: Read this recent paper in which @ESmithMDPhD, Renier Brentjens, @fdezdelarrea, and colleagues prese…
RT @BCD_AACR: Now presenting at #ASH20: Read this recent paper in which @ESmithMDPhD, Renier Brentjens, @fdezdelarrea, and colleagues prese…
RT @BCD_AACR: Now presenting at #ASH20: Read this recent paper in which @ESmithMDPhD, Renier Brentjens, @fdezdelarrea, and colleagues prese…
Now presenting at #ASH20: Read this recent paper in which @ESmithMDPhD, Renier Brentjens, @fdezdelarrea, and colleagues present approaches for simultaneously targeting BCMA and GPRC5D #myeloma antigens by a single #CART infusion. https://t.co/r2KA0JPivD h
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
ICYMI: @ESmithMDPhD, Renier Brentjens, and colleagues present approaches for simultaneously targeting BCMA and GPRC5D #myeloma antigens by a single #CART infusion. https://t.co/3UlCL2pe2y https://t.co/GXexBt2AH6
RT @CARTTherapy: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Esc…
RT @JonathanKhan7: Check out some new work from @ESmithMDPhD and @fdezdelarrea Identifying a strategy for targeting alternative antigens wi…
RT @JonathanKhan7: Check out some new work from @ESmithMDPhD and @fdezdelarrea Identifying a strategy for targeting alternative antigens wi…
RT @JonathanKhan7: Check out some new work from @ESmithMDPhD and @fdezdelarrea Identifying a strategy for targeting alternative antigens wi…
Check out some new work from @ESmithMDPhD and @fdezdelarrea Identifying a strategy for targeting alternative antigens with CAR T cells following antigen loss in MM https://t.co/qfOdA3zdbD
RT @CARTTherapy: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Esc…
RT @CARTTherapy: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Esc…
New article: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma. https://t.co/r1VQW0moSl #MMSM #MultipleMyeloma #hematology https://t.co/FZk6JvKaC
RT @CARTTherapy: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Esc…
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in #Multiple Myeloma https://t.co/vHg2U123ku #CART #bmtsm #CARTcell #immunotherapy #tcellrx #ICAN #CRS #CARTcells
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @LUMICKS_nl: Expressing two CARs on a single #Tcell enhances the binding efficacy for dual-antigen-expressing target cancer cells and he…
RT @LUMICKS_nl: Expressing two CARs on a single #Tcell enhances the binding efficacy for dual-antigen-expressing target cancer cells and he…
Expressing two CARs on a single #Tcell enhances the binding efficacy for dual-antigen-expressing target cancer cells and helps prevent relapsed multiple #myeloma. Check it out in this article ➡️ https://t.co/iQtzNaHmdo or join our webinar to learn more ⬇️
RT @hotirishmonkey: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA…
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma | Blood Cancer Discovery https://t.co/aN7yUF3LEX
RT @Dr_Brodeur: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Esca…
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma https://t.co/1z6kyGZzAt